Cullinan Therapeutics, Inc. (CGEM) vs Damora Therapeutics, Inc. (DMRA)
A side-by-side comparison of Cullinan Therapeutics, Inc. and Damora Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CGEM
Cullinan Therapeutics, Inc.
$16.25HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
DMRA
Damora Therapeutics, Inc.
$19.55HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CGEM vs DMRA
growth of $100 · dividends reinvested · last 6yCGEM -46.4% (-9.9%/yr)DMRA -93.8% (-37.1%/yr)CGEM compounded faster over this window
Log scale — wide-divergence pair
CGEM DMRA
CGEM vs DMRA: by the numbers
- •DMRA is the larger company ($1.20B vs $999M market cap).
Metrics side by side
Valuation
| Metric | CGEM | DMRA |
|---|---|---|
| P/B ratio | 3.10 | 3.12 |
Profitability
| Metric | CGEM | DMRA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -63.62% | -50.93% |
| ROIC | -68.64% | -52.44% |
Growth (annualized)
| Metric | CGEM | DMRA |
|---|---|---|
| Total return CAGR (5Y) | -7.48% | -25.05% |
Frequently asked
- How have CGEM and DMRA total returns compared?
- Over the past 5 years, CGEM delivered -7.48% and DMRA delivered -25.05% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.